retatrutide trial of next-gen weight-loss drug brings it one step closer to FDA approval Retatrutide Shows 28% Weight Loss

The other option is for labs and researchers to buy from "research-use-only" vendors, who provide peptides with no prescription requirement, at a much lower cost

Healthy habits can start at work with something as simple as encouraging more movement in the office or promoting healthy eating

Best for Compounded Tirzepatide 9.5 Overall Score 3

References Jastreboff AM, Kaplan LM, Fras JP, et al

If MHRA approval arrives in late 2027 to mid-2028, private availability could follow within weeks, as it did with Mounjaro and Wegovy

In Phase 3 TRIUMPH-1 data, dysesthesia occurred in 5.1%, 12.3%, and 12.5% of participants taking retatrutide 4 mg, 9 mg, and 12 mg, compared with 0.9% of participants receiving placebo